Assessing sensitivity and similarity in bridging studies

Shein Chung Chow, Jun Shao, Oliver Yoa Pu Hu

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

In pharmaceutical industry, the sponsors are interested in bringing their drug products from one region (e.g., the United States of America) to another region (e.g., Asian Pacific) to increase the exclusivity of the drug products in the marketplace. However, it is a concern whether the clinical results can be extrapolated from the target patient population in one region to a similar but different patient population in a new region due to a possible difference in ethnic factors. The International Conference on Harmonization (ICH) recommends that a bridging study may be necessarily conducted to extrapolate the clinical results between regions. However, little or no information regarding the criterion for determining whether a bridging study is necessary based on the evaluation of the complete clinical data package is provided by the ICH. Furthermore, no criterion on the assessment of similarity of clinical results between regions is given. In this paper, we propose the use of a sensitivity index as a possible criterion for regulatory authorities in the new region to evaluate whether a bridging clinical study should be conducted and the sample size of such a bridging clinical study. A criterion and a statistical method for assessment of similarity of clinical results between regions are also proposed, using the concept of population bioequivalence [FDA. Guidance for Industry - Statistical Approaches to Establishing Bioequivalence, Center for Drug Evaluation and Research, Food and Drug Administration: Rockville, MD, 2001] assuming that study site is random.

Original languageEnglish
Pages (from-to)385-400
Number of pages16
JournalJournal of Biopharmaceutical Statistics
Volume12
Issue number3
DOIs
Publication statusPublished - Nov 25 2002
Externally publishedYes

Fingerprint

Therapeutic Equivalency
Drug Evaluation
Health Services Needs and Demand
Drug Industry
United States Food and Drug Administration
Pharmaceutical Preparations
Sample Size
Population
Industry
Drugs
Bioequivalence
Extrapolate
Clinical Studies
Similarity
Pharmaceuticals
Evaluation
Statistical method
Guidance
Target
Necessary

Keywords

  • Generalizability
  • Reproducibility
  • Sample size
  • Sensitivity index
  • Similarity

ASJC Scopus subject areas

  • Statistics and Probability
  • Pharmacology
  • Pharmacology (medical)

Cite this

Assessing sensitivity and similarity in bridging studies. / Chow, Shein Chung; Shao, Jun; Hu, Oliver Yoa Pu.

In: Journal of Biopharmaceutical Statistics, Vol. 12, No. 3, 25.11.2002, p. 385-400.

Research output: Contribution to journalArticle

Chow, Shein Chung ; Shao, Jun ; Hu, Oliver Yoa Pu. / Assessing sensitivity and similarity in bridging studies. In: Journal of Biopharmaceutical Statistics. 2002 ; Vol. 12, No. 3. pp. 385-400.
@article{b056e4a64b374534bce373bdb474fd8d,
title = "Assessing sensitivity and similarity in bridging studies",
abstract = "In pharmaceutical industry, the sponsors are interested in bringing their drug products from one region (e.g., the United States of America) to another region (e.g., Asian Pacific) to increase the exclusivity of the drug products in the marketplace. However, it is a concern whether the clinical results can be extrapolated from the target patient population in one region to a similar but different patient population in a new region due to a possible difference in ethnic factors. The International Conference on Harmonization (ICH) recommends that a bridging study may be necessarily conducted to extrapolate the clinical results between regions. However, little or no information regarding the criterion for determining whether a bridging study is necessary based on the evaluation of the complete clinical data package is provided by the ICH. Furthermore, no criterion on the assessment of similarity of clinical results between regions is given. In this paper, we propose the use of a sensitivity index as a possible criterion for regulatory authorities in the new region to evaluate whether a bridging clinical study should be conducted and the sample size of such a bridging clinical study. A criterion and a statistical method for assessment of similarity of clinical results between regions are also proposed, using the concept of population bioequivalence [FDA. Guidance for Industry - Statistical Approaches to Establishing Bioequivalence, Center for Drug Evaluation and Research, Food and Drug Administration: Rockville, MD, 2001] assuming that study site is random.",
keywords = "Generalizability, Reproducibility, Sample size, Sensitivity index, Similarity",
author = "Chow, {Shein Chung} and Jun Shao and Hu, {Oliver Yoa Pu}",
year = "2002",
month = "11",
day = "25",
doi = "10.1081/BIP-120014567",
language = "English",
volume = "12",
pages = "385--400",
journal = "Journal of Biopharmaceutical Statistics",
issn = "1054-3406",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Assessing sensitivity and similarity in bridging studies

AU - Chow, Shein Chung

AU - Shao, Jun

AU - Hu, Oliver Yoa Pu

PY - 2002/11/25

Y1 - 2002/11/25

N2 - In pharmaceutical industry, the sponsors are interested in bringing their drug products from one region (e.g., the United States of America) to another region (e.g., Asian Pacific) to increase the exclusivity of the drug products in the marketplace. However, it is a concern whether the clinical results can be extrapolated from the target patient population in one region to a similar but different patient population in a new region due to a possible difference in ethnic factors. The International Conference on Harmonization (ICH) recommends that a bridging study may be necessarily conducted to extrapolate the clinical results between regions. However, little or no information regarding the criterion for determining whether a bridging study is necessary based on the evaluation of the complete clinical data package is provided by the ICH. Furthermore, no criterion on the assessment of similarity of clinical results between regions is given. In this paper, we propose the use of a sensitivity index as a possible criterion for regulatory authorities in the new region to evaluate whether a bridging clinical study should be conducted and the sample size of such a bridging clinical study. A criterion and a statistical method for assessment of similarity of clinical results between regions are also proposed, using the concept of population bioequivalence [FDA. Guidance for Industry - Statistical Approaches to Establishing Bioequivalence, Center for Drug Evaluation and Research, Food and Drug Administration: Rockville, MD, 2001] assuming that study site is random.

AB - In pharmaceutical industry, the sponsors are interested in bringing their drug products from one region (e.g., the United States of America) to another region (e.g., Asian Pacific) to increase the exclusivity of the drug products in the marketplace. However, it is a concern whether the clinical results can be extrapolated from the target patient population in one region to a similar but different patient population in a new region due to a possible difference in ethnic factors. The International Conference on Harmonization (ICH) recommends that a bridging study may be necessarily conducted to extrapolate the clinical results between regions. However, little or no information regarding the criterion for determining whether a bridging study is necessary based on the evaluation of the complete clinical data package is provided by the ICH. Furthermore, no criterion on the assessment of similarity of clinical results between regions is given. In this paper, we propose the use of a sensitivity index as a possible criterion for regulatory authorities in the new region to evaluate whether a bridging clinical study should be conducted and the sample size of such a bridging clinical study. A criterion and a statistical method for assessment of similarity of clinical results between regions are also proposed, using the concept of population bioequivalence [FDA. Guidance for Industry - Statistical Approaches to Establishing Bioequivalence, Center for Drug Evaluation and Research, Food and Drug Administration: Rockville, MD, 2001] assuming that study site is random.

KW - Generalizability

KW - Reproducibility

KW - Sample size

KW - Sensitivity index

KW - Similarity

UR - http://www.scopus.com/inward/record.url?scp=0036428658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036428658&partnerID=8YFLogxK

U2 - 10.1081/BIP-120014567

DO - 10.1081/BIP-120014567

M3 - Article

C2 - 12448579

AN - SCOPUS:0036428658

VL - 12

SP - 385

EP - 400

JO - Journal of Biopharmaceutical Statistics

JF - Journal of Biopharmaceutical Statistics

SN - 1054-3406

IS - 3

ER -